Chst15-IN-1 is a potent reversible covalent Chst15 inhibitor. Chst15-IN-1 effectively inhibits chondroitin sulfate-E ( CS-E ) sulfation levels and other closely related glycosaminoglycans (GAG) sulfotransferases . Chst15-IN-1, as a selective sulfotransferase inhibitor, can diminish the inhibitory effects of chondroitin sulfate proteoglycans (CSPGs), and can be used for the stimulation of neuronal repair.

Chst15-IN-1 (25 μM; 24 hours; Neu7 astrocytes) is selective for sulfotransferases over the myriad of reactive cysteine-containing proteins. Chst15-IN-1 (10 and 25 μM; Neu7 astrocytes) shows a significant dose dependent decrease in cell-surface CS-E expression[1].

Chst15-IN-1 (3.0 mg/kg; i.v.) has a moderate clearance of 21 mL/min/kg, moderate volume of distribution of 0.97 L/kg, and short terminal half-life of 1.6 hours[1]. Animal Model: Rats Dosage: 3.0 mg/kg (Pharmacokinetic Analysis) Administration: I.v. Result: Had a moderate clearance of 21 mL/min/kg, moderate volume of distribution of 0.97 L/kg, and short terminal half-life of 1.6 h.

2158198-77-5

C17H11BrCl2N2O3

442.09

Chst15-IN-1;Chst15-IN-1

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years